- In 2023, Acacia Pharma introduced Barhemsys and Amisulpride as primary antiemetics for managing PONV. Barhemsys, an intravenous selective dopamine D2 and D3 receptor antagonist, effectively prevents and treats PONV, gaining regulatory approval in the US and Europe for its high efficacy
- In 2023, Roche developed a patient-controlled analgesia (PCA) system for PONV. This system administers opioids and antiemetics via a pump, significantly reducing PONV incidence and enhancing patient satisfaction
